Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New technologies in therapeutic antibody development.

O H Brekke1, G Å Løset

  • 1Affitech New Technologies, Gaustadalleen 21, N-0349 Oslo, Norway. o.h.brekke@affitech.com

Current Opinion in Pharmacology
|October 16, 2003
PubMed
Summary

Phage display technology has revolutionized therapeutic antibody development, leading to the first FDA-approved antibody from this platform. This advancement highlights the versatility of antibodies in treating various diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A public T cell receptor recognized by a monoclonal antibody specific for the D-J junction of the β-chain.

Scandinavian journal of immunology·2013
Same author

Functional phage display of two murine alpha/beta T-cell receptors is strongly dependent on fusion format, mode and periplasmic folding assistance.

Protein engineering, design & selection : PEDS·2007
Same author

Characterization of an FcgammaRI-binding peptide selected by phage display.

Protein engineering, design & selection : PEDS·2006
Same author

Neutralizing human antibodies to varicella-zoster virus (VZV) derived from a VZV patient recombinant antibody library.

The Journal of general virology·2004
Same author

Troybodies and pepbodies.

Biochemical Society transactions·2002
Same author

Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.

Molecular immunology·2001

Area of Science:

  • Biotechnology
  • Immunology
  • Drug Discovery

Background:

  • Therapeutic antibodies are crucial for treating diseases like cancer and autoimmune disorders.
  • Phage display technology has emerged as a powerful tool in antibody development over the past decade.

Purpose of the Study:

  • To highlight the impact of phage display technology on therapeutic antibody development.
  • To underscore the significance of the first FDA-approved antibody derived from phage display.

Main Methods:

  • Review of advancements in antibody discovery platforms.
  • Analysis of the role of phage display in generating therapeutic antibodies.

Main Results:

  • The first antibody developed using phage display technology has received FDA approval.

Related Experiment Videos

  • Phage display has significantly contributed to the advancement of antibody-based therapeutics.

    • Conclusions:

    • Phage display technology has proven its efficacy and is a key platform for developing novel therapeutic antibodies.
    • The versatility of antibodies as diagnostic and therapeutic agents is continuously being expanded through innovative platforms.